ADC Therapeutics to Participate in the Jefferies London Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
LAUSANNE, Switzerland--(BUSINESS WIRE)--
ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 15th at 9:45 a.m. GMT.
A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics’ website, ir.adctherapeutics.com. A replay of the webcast will be available for approximately 30 days.
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs). The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.
ADC Therapeutics’ CD19-directed ADC ZYNLONTA® (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large b-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents. Cami (camidanlumab tesirine) is being evaluated in a pivotal Phase 2 trial for relapsed or refractory Hodgkin lymphoma and in a Phase 1b clinical trial for various advanced solid tumors. In addition to ZYNLONTA and Cami, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.
ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit https://adctherapeutics.com/ and follow the Company on Twitter and LinkedIn.
ZYNLONTA® is a registered trademark of ADC Therapeutics SA.
When is ADC Therapeutics' CEO participating in the Jefferies London Healthcare Conference?
Ameet Mallik, CEO of ADC Therapeutics, will participate on November 15 at 9:45 a.m. GMT.
Where can I watch the ADC Therapeutics presentation at the Jefferies London Healthcare Conference?
The presentation will be available live on ADC Therapeutics' Investors page at ir.adctherapeutics.com.
What is ZYNLONTA and its significance for ADC Therapeutics?
ZYNLONTA is an FDA-approved ADC for treating relapsed diffuse large B-cell lymphoma, showcasing ADC Therapeutics' advancements in cancer treatment.
What type of technology does ADC Therapeutics utilize?
ADC Therapeutics utilizes next-generation, targeted antibody drug conjugates (ADCs) for cancer treatment.
What is the purpose of the Jefferies London Healthcare Conference?
The Jefferies London Healthcare Conference serves as a platform for healthcare companies like ADC Therapeutics to discuss advancements and strategies in the industry.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
